Colombia’s biodiversity is a unique source of high-value health compounds
Leveraging validated ethnobotanical knowledge and licensed intellectual property from the research group of Professor Susana Fiorentino, DreemBio (Colombia, 2019) and Phairilab (France, 2024) were founded with a clearmission: to unlock the commercial and therapeutic potential of biodiversity whileadvancing a real, sustainable bioeconomy.
DreemBio has built an integrated value chain — from raw material sourcing with regional and academic partners to proprietary extraction protocols and early-phase clinicalvalidation — all supported through non-dilutive funding. This positions the company todeliver innovative, over-the-counter (OTC) and early-polymolecular health products thatgenerate both clinical value and local economic impact.
Phairilab drives the international strategy, ending the devellopment of Pharma products and targeting high-value pharmaceutical markets in the Global North, aligned with EMA and FDA regulatory frameworks. Our model combines sustainability, science, and marketaccess to build a scalable business ecosystem based on knowledge-driven growth.
Agriculture & Community Impact
Our model begins in the field. We collaborate with small and medium-scale farmers in Colombia to cultivate Anamú, Dividivi and other native species under traceable, fair-practice frameworks.
Through technical support, guaranteed purchasing schemes and agro-industrial upgrading, we transform local biodiversity into high-value bioactive compounds — without extractivism.
This approach demonstrates that advanced biotechnology can be rural, circular and equitable.
“Every scientific breakthrough we make is a shared achievement between those who cultivate the soil and those who innovate in the lab.”
